JPRN-UMIN000009942招募中未知
Comparison of anti-proteinuric effects of febuxostat and conventional therapies for hyperuricemia in patients with chronic kidney disease: an open-label randomized controlled trial - Reno-protective Effect of Febuxostat in Renal-dysfunctional Secondary Hyperuricemia (Tohoku REFRESH study)
Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine0 个研究点目标入组 70 人开始时间: 2013年2月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) High-risk patients requiring dialysis or renal transplantation within 48 weeks 2) History of gout 3) Patients with Cancer or liver disease (HBV/HCV hepatitis, cirrhosis, and the other liver injuries showing AST/ALT values more than twice as high of normal values 4) HbA1c (JDS) >-7.0% with 2 months prior to the entry 5) Office systolic blood pressure >-160 mmHg or diastolic blood pressure >-100 mmHg both at recent twice office visits before the entry 6) Severe heart failure or edema 7) History of renal replacement therapy 8) History of febuxostat intake within four weeks before the entry 9) History of hypersensitivity to allopurinol, benzbromarone, or febuxostat 10) Judged as ineligible in the opinion of the attending physician 11) Pregnancy or nursing
研究者
相似试验
已完成
不适用
comparison of two drugs which lowers proteinuria in diabetic kidney diseaseCTRI/2012/04/002550Sowmya Bondalapati100
已完成
2 期
Effect of pentoxifylline on urinary protein excretion reduction in diabetic nephropathy patients.Condition 1: Non-insulin-dependent diabetes mellitust. Condition 2: Diabetic Nephropathy.Non-insulin-dependent diabetes mellitusGlomerular disorders in diabetes mellitusIRCT138901013596N1research deputy of Ahvaz Jundishapur University100
已完成
不适用
Evaluation for antiatherogenic efficacy of febuxostat in patients with hyperuricemiaHyperuricemiaJPRN-UMIN000009134Department of Medicine and Bioregulatory Sciences20
已完成
4 期
antiproteinuric and antiinflammatory effect of vitamin D comparing with direct renin inhibitor in DKDAge > 18DKD with eGFR > 15 ml/min Optimal dose of ACEI or ARB 𕟵 monthsStable BP control ( ΔSBP 󖼚% )Stable renal function ( ΔeGFR 󖼚% )Stable glycemic cvitamin D ,Direct renin inhibitor ,diabetic kidney diseaseTCTR20120000008avamindhradhiraj university39
已完成
不适用
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia in chronic kidney disease.Hyperuricemic patients with CKDJPRN-UMIN000005573Yokohama City University Medical Center40